The aim of the study was to model the local data on the costs and health benefits of alternative antiviral therapies for the prevention and treatment of CMV seropositive patients after HSCT and to perform an indirect comparison based on meta-analysis. Input data in the model are the measured and evaluated clinical endpoints in the randomized multicentre clinical trial MK-8228-001. The modeling of the data for future health benefits and costs after the end of the clinical trials was conducted using a Markov model with 6 health conditions and 1 absorbent state. The model includes all possible health conditions reflecting the course of the disease and all the probabilities of transition from one health condition to another are envisaged. Input data in the model are the primary and secondary endpoints in the randomized clinical trial MK-8228-001 - clinically significant CMV infection at weeks 12 and 24, preemptive therapy for CMV viremia and CMV-related terminal organ diseases.
The time horizon of the model is lifelong. Costs and benefits are discounted at 5% per annum. The perspective chosen is the point of view of the third party payer. The conclusion of the evaluations is that letermovir dominates valganciclovir with improved therapeutic efficacy and lower cost of treatment for cytomegalovirus-seropositive patients after allogeneic hematopoietic stem cell transplantation.
Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (Eds.). Cambridge: Cambridge University Press; 2007.
Felfly H, Haddad GG. Hematopoietic stem cells: potential new applications for translational medicine. J Stem Cells. 2014, 9(3):163-97.
Демирева-Калчева, Ж. Серологични и молекулярно-генетични проучвания на цитомегаловирусната инфекция при рискови групи. Автореф., МУ – Варна, 2018.
Park B, Yoo KH, Kim C. Hematopoietic stem cell expansion and generation: the ways to make a breakthrough. Blood Res. 2015, Dec;50(4):194-203.
Marty FM, Ljungman P, Chemaly RF et al. Letermovir prophylaxis for Cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017, Dec 21;377(25):2433-44.
Chou S. Rapid in vitro evolution of human Cytomegalovirus UL56 mutations that confer Letermovir resistance. Antimicrob Agents Chemother. 2015, Oct;59(10):6588-93.
Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988, Jul-Aug;10 Suppl 3:S490-4.
McIntosh M, Hauschild B, Miller V. Human cytomegalovirus and transplantation: drug development and regulatory issues. J Virus Erad. 2016, Jul 1;2(3):143-8.
Grigorov E, Vaseva V, Getov I. Applied pharmacoeconomics- methodology structuring and conducting of pharmacoeconomical studies. Journal of International Scientific Publication: Economy & Business. 2013, 7(1): 540-51.
Shtereva D. Types of methods of economic evaluations in the healthcare sector. Journal of International Scientific Publication: Economy & Business. 2010, 4(4):4-11.
Ramsey SD, Willke RJ, Glick H et al. Cost-effectiveness analysis alongside clinical trials II – An ISPOR Good Research Practices Task Force report. Value Health. 2015, Mar;18(2):161-72.
Schelfhout J, Jiang Y, Miles LS, et al. Cost effectiveness of Letermovir as Cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Biology of blood and marrow transplantation. 2018, 24(3), Suppl., S384.
Ciceri F, Restelli U, Croce D, et al. Cost utility analysis of the use of Letermovir for the prophylaxis of Cytomegalovirus in patients undergoing allogenic hematopoietic stem cell transplant – two scenario analyses from Italy. European Hematology Association, Abstract: PF702, 2018.
Letermovir for preventing cytomegalovirus disease after a stem cell transplant. National Institute for Health and Care Excellence. June 2018.
Silvins J, S. Alessi-Severini, A. Bayoumi et al. Letermovir (cytomegalovirus infection, prophylaxis). CADTH Drug Reimbursement Recommendation, June 2018.
Email this article (Login required) 
